Brimapitide

Drug Profile

Brimapitide

Alternative Names: AM-111; AM111 peptide; D-JNKI-1; XG-102; XG102 peptide

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator Xigen
  • Developer Auris Medical; ribOvax Biotechnologies; Xigen
  • Class Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Peptides
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ocular inflammation; Sensorineural hearing loss
  • Phase I Stroke
  • No development reported Eye disorders; Myocardial infarction; Parkinson's disease; Transplant rejection
  • Discontinued Ear disorders

Most Recent Events

  • 17 Jun 2016 Phase-III clinical trials in Sensorineural hearing loss in Canada (Intratympanic)
  • 17 Jun 2016 Phase-III clinical trials in Sensorineural hearing loss in South Korea (Intratympanic)
  • 17 Jun 2016 Phase-III clinical trials in Sensorineural hearing loss in USA (Intratympanic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top